Vertex Pharmaceuticals Inc

VRTX remains in a Stage 2 advancing regime within a secular uptrend, with medium-term bias bullish supported by higher highs and price above the rising 50-day MA. However, short-term momentum has turned negative, with price rejected at the 9/21 EMA band and overbought conditions evident. Using a SPEC strategy, we will stalk for a pullback into the 21 EMA / 50 DMA support region and require clear acceptance before committing.

• ↑Q1 2026 revenue rose 8% YoY to $2.99B driven by CF therapy demand
• ↑Acquisition of Crinetics for $10B adds endocrine pipeline with $5B+ peak potential
• ↓Shares trade at high valuation, risking correction if growth misses forecasts